SaaS MVP Development · Boston, MA

SaaS MVP development in Boston.

Boston MVPs grow up near institutions: hospitals with security reviews, universities with procurement offices, biotechs with quality systems. Founders here are often building from deep domain expertise into markets where the pilot paperwork outweighs the product, and the build has to be ready for both.

We build SaaS MVPs end to end: Next.js and TypeScript on Postgres, SSO-ready auth, Stripe billing, HIPAA scoping where PHI is real, and production deployment with the security documentation institutions request. You own everything.

How we work

Tell us the product and the institution that will pilot it.

The technical reality of shipping an MVP in Boston.

The PHI decision is the budget decision. Version one on de-identified or synthetic data ships months earlier and tens of thousands cheaper; version one on real patient data carries BAA-eligible infrastructure, audit logging, and review-ready documentation from day one. We force that decision in scoping, design the architecture so the compliant path is an upgrade rather than a rewrite, and spend your money on whichever side the evidence supports.

Institutional pilots are won on friction: SSO instead of password accounts, role models that mirror the org chart, a data-flow diagram ready before they ask, and a pilot design that needs one champion and zero IT projects on their side.

The device line is real. Administrative and workflow software sits safely outside FDA's definition; software informing clinical decisions about individual patients may not. We build confidently on the administrative side, name the line in writing, and insist on regulatory counsel before any roadmap crosses it.

Boston's talent market shapes the handoff: your eventual hires will be strong and opinionated, so the codebase is standard, typed, documented, and boring in the way senior engineers respect. The architecture document explains every decision while the reasoning is fresh.

What an MVP engagement includes.

The standard build, tuned for Boston's institutional markets.

Core workflow, end to end

Next.js, TypeScript, Postgres. The product's one essential loop built completely, on synthetic data first if that ships pilots sooner.

PHI scoping and HIPAA build

An explicit decision on whether version one touches PHI, and the BAA-eligible infrastructure, audit logging, and documentation when it does.

Institution-ready auth

SSO-ready authentication, role-based access that maps to hospital and university org structures, and session policies reviewers expect.

Security-review package

Data-flow diagrams, encryption and access documentation, and questionnaire-ready answers produced as deliverables, not scrambles.

AI features inside the compliance frame

Model features on BAA-eligible inference where they serve the workflow, with eval sets and the audit logging PHI demands.

Phased build architecture

Phase one spends only what the next milestone needs; the architecture quietly carries phase two so compliance is an upgrade, not a rewrite.

Built for Boston's institutional economy.

Boston founders disproportionately build where the city's institutions are: digital health against the hospital systems, research tooling against the biotech corridor, edtech against the universities. Those markets reward credibility artifacts as much as product: the security packet, the SSO login, the pilot that asks nothing of the institution's IT department. We build MVPs that arrive with those artifacts in hand.

The same institutions supply the talent you will eventually hire, which raises the bar on code quality in a useful way: the deliverable has to survive the scrutiny of the senior engineer you recruit next year, and it is built accordingly.

We work with Boston founders remotely, with weekly working demos on video in Eastern hours and written decision logs between them.

Questions from Boston founders.

Do we need HIPAA compliance from day one, and what does it add to the build?: Only if version one actually touches PHI, and that is a scoping decision worth real money. If your design partners will pilot with de-identified or synthetic data, you can defer the compliance build and ship months earlier; if the product is useless without real patient data, HIPAA is day-one scope. What it adds concretely: BAA-eligible infrastructure (your cloud provider and any AI vendor under BAA), encryption and access controls beyond consumer defaults, audit logging on PHI access, session and device policies, and the documentation a hospital's security review will request. Budget-wise it typically moves a build from the lower half of our range into the upper half. The expensive mistake is the middle path: handling PHI casually and retrofitting compliance during your first health-system negotiation.
What does it take for a hospital or university to pilot an MVP?: More paperwork than product, and the MVP should be built knowing that. Health systems and universities run procurement and security reviews even for pilots: expect a security questionnaire (often hundreds of items), proof of data handling (encryption, access logs, breach process), insurance requirements, and a legal review of your terms. The build supports this with SSO readiness (institutions hate password accounts), role-based access that maps to their org structure, audit logs, and a data-flow diagram we produce as a standard deliverable. Equally important is what the pilot asks of them: the successful Boston pattern is a pilot that needs one champion and no IT project on their side, which means your product does its own integration lifting through exports, APIs, or standalone workflows first.
Our product analyzes health data. When does it become a regulated medical device?: When it starts informing clinical decisions about individual patients, and that line deserves respect early. Software that handles scheduling, documentation, administrative workflows, or population-level analytics generally sits outside FDA's device definition. Software that diagnoses, treats, or drives clinical decision-making about a specific patient can be Software as a Medical Device, with a regulatory pathway that is a different project entirely. Many Boston MVPs sensibly launch on the administrative side of that line while the clinical ambitions wait for funding and regulatory counsel. We are engineers, not regulatory counsel, and we say so: if your roadmap crosses into SaMD territory, we will build the non-device MVP and insist you get proper regulatory advice for the rest. Pretending the line is not there is how startups acquire FDA letters.
Seed-stage budget, institutional ambitions: how do we sequence the build?: Sequence by what the next milestone requires, not by what the vision deserves. A typical Boston path: phase one ships the core workflow with synthetic or de-identified data, SSO-ready auth, and the security documentation that gets institutional conversations started; that is enough to run pilots, gather letters of intent, and raise. Phase two adds the HIPAA build and the first real integration once a signed pilot justifies them. The discipline is refusing to build phase two's compliance before phase one has evidence, while never building phase one in a way that makes phase two a rewrite. We design the architecture for the second phase and spend money only on the first.

Ready to scope your MVP?

Tell us the product, whether PHI is in version one, and which institution you are courting. We reply within one business day with a rough scope and a fixed price range.

SaaS MVP development in Boston.

The technical reality of shipping an MVP in Boston.

What an MVP engagement includes.

The standard build, tuned for Boston's institutional markets.

Core workflow, end to end

Next.js, TypeScript, Postgres. The product's one essential loop built completely, on synthetic data first if that ships pilots sooner.

PHI scoping and HIPAA build

An explicit decision on whether version one touches PHI, and the BAA-eligible infrastructure, audit logging, and documentation when it does.

Institution-ready auth

SSO-ready authentication, role-based access that maps to hospital and university org structures, and session policies reviewers expect.

Security-review package

Data-flow diagrams, encryption and access documentation, and questionnaire-ready answers produced as deliverables, not scrambles.

AI features inside the compliance frame

Model features on BAA-eligible inference where they serve the workflow, with eval sets and the audit logging PHI demands.

Phased build architecture

Phase one spends only what the next milestone needs; the architecture quietly carries phase two so compliance is an upgrade, not a rewrite.

Built for Boston's institutional economy.

We work with Boston founders remotely, with weekly working demos on video in Eastern hours and written decision logs between them.

Questions from Boston founders.

Do we need HIPAA compliance from day one, and what does it add to the build?

Only if version one actually touches PHI, and that is a scoping decision worth real money. If your design partners will pilot with de-identified or synthetic data, you can defer the compliance build and ship months earlier; if the product is useless without real patient data, HIPAA is day-one scope. What it adds concretely: BAA-eligible infrastructure (your cloud provider and any AI vendor under BAA), encryption and access controls beyond consumer defaults, audit logging on PHI access, session and device policies, and the documentation a hospital's security review will request. Budget-wise it typically moves a build from the lower half of our range into the upper half. The expensive mistake is the middle path: handling PHI casually and retrofitting compliance during your first health-system negotiation.

What does it take for a hospital or university to pilot an MVP?

More paperwork than product, and the MVP should be built knowing that. Health systems and universities run procurement and security reviews even for pilots: expect a security questionnaire (often hundreds of items), proof of data handling (encryption, access logs, breach process), insurance requirements, and a legal review of your terms. The build supports this with SSO readiness (institutions hate password accounts), role-based access that maps to their org structure, audit logs, and a data-flow diagram we produce as a standard deliverable. Equally important is what the pilot asks of them: the successful Boston pattern is a pilot that needs one champion and no IT project on their side, which means your product does its own integration lifting through exports, APIs, or standalone workflows first.

Our product analyzes health data. When does it become a regulated medical device?

When it starts informing clinical decisions about individual patients, and that line deserves respect early. Software that handles scheduling, documentation, administrative workflows, or population-level analytics generally sits outside FDA's device definition. Software that diagnoses, treats, or drives clinical decision-making about a specific patient can be Software as a Medical Device, with a regulatory pathway that is a different project entirely. Many Boston MVPs sensibly launch on the administrative side of that line while the clinical ambitions wait for funding and regulatory counsel. We are engineers, not regulatory counsel, and we say so: if your roadmap crosses into SaMD territory, we will build the non-device MVP and insist you get proper regulatory advice for the rest. Pretending the line is not there is how startups acquire FDA letters.

Seed-stage budget, institutional ambitions: how do we sequence the build?

Sequence by what the next milestone requires, not by what the vision deserves. A typical Boston path: phase one ships the core workflow with synthetic or de-identified data, SSO-ready auth, and the security documentation that gets institutional conversations started; that is enough to run pilots, gather letters of intent, and raise. Phase two adds the HIPAA build and the first real integration once a signed pilot justifies them. The discipline is refusing to build phase two's compliance before phase one has evidence, while never building phase one in a way that makes phase two a rewrite. We design the architecture for the second phase and spend money only on the first.

Ready to scope your MVP?

Tell us the product, whether PHI is in version one, and which institution you are courting. We reply within one business day with a rough scope and a fixed price range.